



CooperVision®  
Control de Miopía

# Descubre porqué CooperVision es líder mundial en control de la miopía para niños y adolescentes.



## MiSight® 1 day



**Optical Characterisation and Vision Quality Assessment of Two Myopia Control Contact Lenses.**

Richards et al. *OPO*. 2025; 00:1–9.



**Eye Growth and Myopia Progression Following Cessation of Myopia Control Therapy with a Dual-focus Soft Contact Lens.**

Chamberlain P et al. *OVS*. 2025; March, In Press.



**Accommodative Behaviour and Retinal Defocus in Highly Myopic Eyes Fitted with a Dual Focus Myopia Control Contact Lens.**

Meyer D et al. *OPO*. 2025; 45: 189–199.



**Six-year Cumulative Treatment Effect and Treatment Efficacy of a Dual Focus Myopia Control Contact Lens.**

Chamberlain P et al. *OPO*. 2024; 44: 199–205.



**Six Years of Wearer Experience in Children Participating in a Myopia Control Study of MiSight® 1 day.**

Lumb E et al. *CLAE*. 2023 Aug; 46(4):101849.



**Myopia Control Dose Delivered to Treated Eyes by a Dual Focus Myopia Control Contact Lens.**

Ramasubramanian V et al. *OVS*. 2023.



**Long-term Effect of Dual-focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial.**

Chamberlain P et al. *OVS*. 2022; 99(3): 204–212.



**Ocular Health of Children Wearing Daily Disposable Contact Lenses Over a 6-year Period.**

Woods J et al. *CLAE*. 2021; 44(4): 101391.



**Axial Length Targets for Myopia Control.**

Chamberlain P et al. *OPO*. 2021; 41(3): 523–531.



**Adverse Event Rates in the Retrospective Cohort Study of Safety of Paediatric Soft Contact Lens Wear: the ReCSS Study.**

Chalmers RL et al. *OPO*. 2021; 41: 84–92.



**A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control.**

Chamberlain P et al. *OVS*. 2019; 96(8): 556–567.

## Paragon CRT® y DreamLite®



**Control of Myopia Using Orthokeratology Lenses in Scandinavian Children Aged 6 to 12 Years. Eighteen-month Data from the Danish Randomized Study: Clinical Study of Near-sightedness; Treatment with Orthokeratology Lenses (CONTROL study).**

Jakobsen TM and Møller F. *Acta Ophthalmologica*. 2022; 100(2): 175–182.



**Corneal Reshaping and Myopia Progression.**

Walline JJ et al. *BJO* 2009; 93(9): 1181–5.

## MiSight® Spectacle Lenses



**Control of Myopia Using Diffusion Optics Spectacle Lenses: 4-year Results of a Multicentre Randomised Controlled, Efficacy and Safety Study (CYPRESS).**

Laughton, D et al. *BMJ Open Ophthalmology* 2024.



**Diffusion Optics Technology (DOT): A Myopia Control Spectacle Lens Based on Contrast Theory.**

Neitz J, Neitz M. *Transl Vis Sci Technol.* 2024; 13(10): 42.



**Visual Impact of Diffusion Optic Technology Lenses for Myopia control.**

Wolffsohn JS et al. *OPO.* 2024; 44: 1398–1406.



**Two-year Effectiveness of a Novel Myopia Management Spectacle Lens with Full Time Wearers.**

Rappon J et al. *IOVS.* 2022; 63(7): 408.



**Tolerability of Novel Myopia Control Spectacle Designs.**

Rappon J et al. *IOVS.* 2019; 60(9): 5845.



## Estudios clínicos apoyados por CooperVision®



**IMI-Onset and Progression of Myopia in Young Adults.**

Bullimore MA et al. *J.* 2023; 64(2).



**Incidence of Corneal Adverse Events in Children Wearing Soft Contact Lenses.**

Bullimore MA et al. *Eye & Contact Lens: Science & Clinical Practice.* 2023; 49(5): 204–211.



**The Risks and Benefits of Myopia Control.**

Bullimore MA et al. *Ophthalmology.* 2021; 128(11): 1561–1579.



**Evidence-based Practice in Myopia Management.**

Wolffsohn J et al. *Optometry in Practice (Online).* 2021; 22(3). ISSN 2517-5696.



**Overnight Orthokeratology.**

Bullimore MA and Johnson LA. *CLAE.* 2020; 43(4): 322–332.



**Myopia Control 2020: Where Are We and Where are We Heading?**

Bullimore MA and Richdale K. *OPO.* 2020; 40(3): 254–270.



**The Safety of Soft Contact Lenses in Children.**

Bullimore MA. *OVS.* 2017; 94(6): 638–646.



## Para más información:

Departamento Técnico, Professional Affairs CooperVision Iberia

[tecnico@coopervision.com](mailto:tecnico@coopervision.com)

Los productos e indicaciones de uso pueden variar según el país.

CooperVision®, DreamLite®, MiSight® y Paragon CRT® son marcas registradas de The Cooper Companies, Inc. y sus subsidiarias. SightGlass Vision, 4970 El Camino Real, Ste 100, 94022 Los Altos, California, U.S.

©2025 CooperVision SA08218 Rev.#7 07/2025



CooperVision®

Control de Miopía